MoH Strengthens Vaccine Production and Research Through Partnership with IVI.

CS for Health, Dr. Deborah M. Barasa and Director General of the International Vaccine Institute Dr. Jerome Kim holding the newly signed MoU.

Kenya through the Ministry of Health (MOH) took a significant step toward self-reliance in vaccine production by signing a Memorandum of Understanding (MoU) with the International Vaccine Institute (IVI) on the 26th of November 2024. The agreement underscores the country’s commitment to advancing vaccine research, development, and health security across Africa.

This signing is a culmination of a tour to the IVI headquarters in Korea on 5th June 2024 by H.E. President William Ruto, who was accompanied by KEMRI Board of Directors Chairman Dr. Abdullahi Ali and KEMRI’s Acting Director General Prof. Elijah Songok. During the trip, the flag-raising ceremony marked Kenya’s formal entry as the 41st member state of IVI, symbolizing the country’s resolve to strengthen vaccine research and production.

Dr. Deborah Barasa, speaking at the MoU signing ceremony, emphasized the significance of the collaboration in meeting Africa CDC’s target of producing 60% of the continent’s vaccines locally by 2040. She stated, “This MoU symbolizes our shared commitment to building a robust vaccine ecosystem that ensures equitable access for all while enhancing health security in Kenya and beyond.”

Kenya’s selection to host the IVI Country Office and the Advancing Vaccine End-to-End Capabilities (AVEC) Project Office reinforces its leadership in health innovation. Dr. Jerome Kim described the partnership as “a bold step forward in advancing global health security through innovative and sustainable vaccine solutions.”

*CS for Health, Dr. Deborah Mulongo making her remarks.*

*Director General of the International Vaccine Institute Dr. Jerome Kim giving his insights during the meeting.*

The partnership will involve Kenyan institutions like the Kenya Medical Research Institute (KEMRI) and Kenya BioVax Institute in vaccine research, clinical trials, disease surveillance, and workforce training. Dr. Michael Lusiola reaffirmed Kenya BioVax’s readiness to produce primary immunization vaccines by 2026, noting the project remains on track.

Prof. Elijah Songok, KEMRI’s Acting Director General, highlighted the importance of collaboration in addressing public health challenges and advancing vaccine research. The partnership builds on KEMRI’s expertise and strengthens the Ministry of Health’s Universal Health Coverage agenda through increased vaccine access and innovation.

*From LtoR; Managing Director/Chief Executive Officer BioVax Institute Dr Michael Lusiola and Ag. Director General, Prof. Elijah Songok following discussions during the meeting.*

*The Delegation present at the MoU Signing.*

The collaboration will also focus on workforce development through institutions like the Kenya Advanced Institute of Science and Technology and pharmaceutical manufacturing through Kenya BioVax Institute. By working with IVI, Kenya aims to improve vaccine access and health security across the continent while preparing for future public health emergencies.